Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HLA-A*24:02–CMV pp65 epitope peptide complex is a molecular assembly consisting of the human leukocyte antigen (HLA) class I molecule A*24:02 and a specific immunodominant peptide derived from the Cytomegalovirus (CMV) 65 kDa phosphoprotein (pp65) (Source: UniProt P06725, P01892). This complex is expressed on the surface of CMV-infected cells, where it serves as a critical recognition element for the adaptive immune system (Source: PubMed 12117466). Specifically, it is recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes, which are essential for controlling CMV infection and preventing viral reactivation in immunocompromised individuals, such as transplant recipients (Source: PubMed 11748283). HLA-A*24:02 is one of the most prevalent HLA alleles in East Asian populations, making this specific complex a high-priority target for precision immunotherapy and vaccine design (Source: PubMed 15654915). Therapeutic strategies targeting this complex include the development of TCR-engineered T cells (TCR-T) and peptide-based vaccines designed to enhance the cellular immune response against CMV (Source: ClinicalTrials.gov NCT02388828). In clinical settings, targeting this complex helps mitigate the risks of CMV-related morbidity and mortality by restoring or augmenting viral-specific immunity. Understanding the structural and binding characteristics of this MHC-peptide complex is vital for ensuring the specificity and safety of TCR-based interventions to avoid off-target effects.
The complex acts as a specific ligand for T-cell receptors (TCRs) found on CD8+ cytotoxic T lymphocytes; binding of the TCR to this pMHC complex triggers T-cell activation, proliferation, and the release of cytotoxic granules (perforin/granzyme) to lyse CMV-infected cells (Source: PubMed 11748283).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human leukocyte antigen A*24:02–Cytomegalovirus phosphoprotein 65 epitope peptide complex (HLA-A*24:02–CMV pp65 complex).